Morphic — Investor Presentation (March 2024)
38 slides from Morphic's investor presentation, Mar 12, 2024
Slide 1: Delivering A New Generation Of Integrin Medicines
Delivering A New Generation Of Integrin Medicines March 2024
Slide 2: Forward-Looking Statements
This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing clinical trials and related data, updates
Slide 3: Unique Receptors: Unique Therapeutic Potential
Unique Receptors: Unique Therapeutic Potential 3 What are integrins? • Only receptor to signal bidirectionally, giving them central biologic roles in complex diseases: autoimmune, fibrotic, cardio-metabolic and oncologic • Expensive, complex biologics have shown clinically meaningful efficacy by tar
Slide 4: MInT Platform: Morphic's Solution to the Oral Integrin Challenge
MInT Platform: Morphic’s Solution to the Oral Integrin Challenge 4 Structural Knowledge Privileged Scaffolds Focused Chemical Libraries Assays Against Tractable Targets Synthetically Tractable “Hits” Computational Chemistry w/ Schrödinger High Quality Probes Pharmacologic Validation of Related Targe
Slide 5: Proprietary Pipeline
Proprietary Pipeline 5 Candidate Target (Program) Indication Discovery IND-enabling Phase 1 Phase 2 Phase 3 MORF-057 α4β7 Ulcerative Colitis Crohn's disease1 Next- generation α4β7 GI Disorders MORF SMI2 IL23, TL1A, etc Immune and Inflammatory Diseases MORF SMI α5β1 Pulmonary Hypertensive Diseases MO
Slide 6: MORF-057 Small molecule inhibitor of α4β7
MORF-057 Small molecule inhibitor of α4β7: a well-validated mechanism to treat IBD EMERALD-2 Phase 2b study ongoing
Slide 7: IBD: Ideal Future Treatment Paradigm
IBD: Ideal Future Treatment Paradigm 7 COMBINABLE ORAL WELL TOLERATED EFFICACIOUS
Slide 8: First-In-Class Oral Integrin Drug for IBD
Indications First-In-Class Oral Integrin Drug for IBD 8 Highly selective orally available small molecule inhibitor of α4β7, well validated mechanism for the treatment of IBD through approved monoclonal antibody vedolizumab MORF-057 Occluding α4β7 blocks intestinal homing of lymphocytes, which in tur
Slide 9: α4β7 Inhibition is a Proven Mechanism to Treat IBD
α4β7 Inhibition is a Proven Mechanism to Treat IBD • Approved antibody Entyvio® (vedolizumab) • Vedolizumab, an anti-α4β7 antibody, inhibits T-cell trafficking via well validated mechanism to treat UC and Crohn’s disease • Since approval, over 265,000 patients have received vedolizumab1 • Vedolizuma
Slide 10: MORF-057 has Consistently Delivered on Expectations for an Oral α4β7 Inhibitor in IBD
MORF-057 has Consistently Delivered on Expectations for an Oral α4β7 Inhibitor in IBD 10 MORF-057 PRECLINICAL PHASE 1 PHASE 2a Oral Route of Administration Favorable Tolerability Profile α4β7 Saturation (serum) 30-50% ↑ in Key Lymphocytes Meaningful Clinical Effects All scientific posters and presen
Slide 11: EMERALD-1 Phase 2a Study of MORF-057
EMERALD-1 Phase 2a Study of MORF-057
Slide 12: MORF-057 Phase 2a: EMERALD-1 Study in Moderate to Severe UC
MORF-057 Phase 2a: EMERALD-1Study in Moderate to Severe UC 12 Study Visits W0 D1 W2 D15 W6 D43 W12 D85 W20 D141 W28 D197 W36 D253 W44 D309 W52/EOT D365 W82/SFU D575 W56/SFU D393 W65 D456 W78/EOT D547 W - 6 to -1 D - 42 to -1 Phase 2a open-label single-arm study of MORF-057 (100mg BID) in patients wi
Slide 13: Baseline Patient Demographics
Category Patients, N=35 Age, mean ± SD Years 39.2 ± 14.1 Sex, n (%) Female 16 (45.7) Geography, n (%) Poland United States 28 (80.0) 7 (20.0) Duration of disease, mean ± SD Years 7.5 ± 8.0 Extent of disease, n (%) Proctosigmoiditis L-sided colitis Pancolitis 12 (34.3) 10 (28.6) 10 (28.6) RHI Score,
Slide 14: EMERALD-1 12-week Induction Phase
EMERALD-1 12-week Induction Phase Data as of 4/25/23
Slide 15: Generally Well-Tolerated in EMERALD-1
Generally Well-Tolerated in EMERALD-1 No Safety Signal Observed 15 Adverse Event (AE) profile consistent with underlying disease state Patients with at least one AE 12 (34.3%) Patients with any serious AE 0 Patients with AE leading to death 0 Patients with any grade 3 AE 2 (5.7%)1 Patients with trea
Slide 16: Patient α4β7 Receptor Occupancy Consistent with Healthy Volunteer RO
Patient a4β7 Receptor Occupancy (RO) Consistent with Healthy Volunteer RO 16 a4β7 selectivity over a4β1 consistent with Phase 1 results RO at 12 weeks a4β7 a4β1 Mean >98% BLQ Median >99% BLQ • a4β7 RO achieved early and sustained saturating levels • a4β1 RO remained at low levels • No lymphocytosis
Slide 17: Fecal Calprotectin Decreases Correlated with Disease Improvement
17 Fecal Calprotectin Decreases Correlated with Disease Improvement 19% 54% 75% Overall (n=29): 35% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Non- Responder (n=16) Clinical Response (n=13) Clinical Remission (n=8) -11% -86% -89% Overall (n=27): -56% -100% -90% -80% -70% -60% -50% -40% -30% -20% -1
Slide 18: Substantial Lymphocyte Subset Changes Observed
18 Substantial Lymphocyte Subset Changes Observed, Consistent With Engagement Of α4β7 0 25 50 75 100 125 150 Weeks N o rm a li z e d % 0 2 6 12 0 25 50 75 100 125 150 200 300 400 Weeks N o rm a li z e d % P = 0.0039 ** 0 2 6 12 P = 0.0298 * 0 25 50 75 100 125 150 200 300 400 Weeks N o rm a li z e d
Slide 19: EMERALD-1 Induction Phase Clinical Efficacy Results
EMERALD-1 Induction Phase Clinical Efficacy Results
Slide 20: Primary Endpoint Met with Statistical Significance
20 Endpoint @ Week 12 Overall (N=35) Change in RHI, Mean (SD) -6.4 (11.18) p=0.0019 RHI remission, n (%) 8 (22.9%) Clinical response (mMCS)1, n (%) 16 (45.7%) Clinical remission (mMCS)2, n (%) 9 (25.7%) Endoscopic Response/Improvement3, n (%) 9 (25.7%) Change from baseline to Week 12 in the Modified
Slide 21: EMERALD-1 Efficacy Results by AT Status and MES
21 EMERALD-1 Efficacy Results by AT Status and MES Endpoint @ Week 12 Overall N=35 AT-naïve n=21 AT- experienced n=14 MES =2 n=18 MES =3 n= 17 Change in RHI, mean ± SD -6.4 ± 11.2 -7.4 ± 11.9 -4.8 ± 10.3 -6.9 ± 12.1 -5.8 ± 10.4 RHI change ≥ 7 points, n (%) 17 (48.6) 12 (57.1) 5 (35.7) 10 (55.6) 7 (4
Slide 22: Consistent Across-the-Board Efficacy Signals Observed
22 Consistent “Across-the-Board” Efficacy Signals Observed Subgroup AT-Experienced Yes (n=14) No (n=21) Corticosteroid Use at Baseline Yes (n=9) No (n=26) Baseline MES 3 (n=17) 2 (n=18) Mean Change (95% CI) -4.8 (-10.7, 1.1) -7.4 (-12.8, -2.0) -5.2 (-11.1, 0.7) -6.8 (-11.7, -1.8) -5.8 (-11.1, -0.4)
Slide 23: Clinical Improvement in >75% of All Patients
23 Clinical Improvement in >75% of All Patients, Regardless of Prior Therapy and Baseline MES 77% 46% 26% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Improvement in mMCS Clinical Response Clinical Remission Overall Clinical Improvement AT-Naïve: n=21; AT-Experienced: n=14 76% 52% 43% 79% 36% 0% 0% 10% 20
Slide 24: Change in Central mMCS By Patient from Baseline
24 Change in Central mMCS By Patient from Baseline at Week 12 -7 -6 -5 -4 -3 -2 -1 0 1 2 C h an ge in m M C S fr o m B as el in e at W ee k 1 2
Slide 25: EMERALD-1 Data Beyond Weeks
EMERALD-1 Data Beyond 12 Weeks
Slide 26: Symptomatic Remission By AT-Status
26 Symptomatic Remission By AT-Status: Week 44 Intent to Treat (ITT): Denominator includes all enrolled patients (N=35) As observed: Denominator includes only patients who completed the visit 14.3 7.1 11.4 42.9 7.1 28.6 47.6 7.1 31.4 42.9 21.4 34.3 47.6 28.6 40 42.9 28.6 37.1 42.9 21.4 34.3 3/21 9/2
Slide 27: MORF-057 Phase 2b: EMERALD-2 Study in Moderate to Severe UC
MORF-057 Phase 2b: EMERALD-2 Study in Moderate to Severe UC 27 Induction Period (12 weeks) Maintenance Period (40 weeks) Primary Endpoint: proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS) W0 D1 W2 D15 W6 D43 W12 D85 W18 D127 W24 D1
Slide 28: GARNET Phase 2 Study in Moderate to Severe Crohn's Disease
GARNET Phase 2 Study of MORF-057 in Moderate to Severe Crohn’s Disease 28 Induction Period (14 weeks) Maintenance Period (38 weeks) Primary Endpoint: proportion of patients with endoscopic response (>=50% reduction) at week 14 as determined using SES-CD Open-label Extension Safety Follow-Up Period S
Slide 29: Emerging Pipeline
EMERGING PIPELINE Creating the next generation of proprietary integrin inhibitor candidates
Slide 30: α5β1: Small Molecule Integrin Inhibitor for Pulmonary Hypertensive Diseases
a5β1: Small Molecule Integrin Inhibitor for Pulmonary Hypertensive Diseases 30 Small molecule inhibitors of fibronectin integrins in preclinical development Program Fibronectin integrin inhibition suppresses pulmonary arterial smooth muscle cell proliferation Indications Multiple pulmonary hypertens
Slide 31: α5β1 Integrin Inhibition for Pulmonary Hypertensive Diseases
Vasoconstriction Arterial remodeling & inflammation Pulmonary Hypertensive Diseases a5β1 Integrin Inhibition for Pulmonary Hypertensive Diseases • Potential applications in severely underserved pulmonary hypertensive diseases • In preclinical studies, Α5β1 inhibition may drive multiple independent p
Slide 32: α5β1 Inhibition Improves Pulmonary Artery Remodeling and Cardiac Function
32 a5b1 Inhibition Improves Pulmonary Artery Remodeling and Cardiac Function Data generated by Sebastien Bonnet, Laval University Mean ± SEM. *p<0.05; **p<0.01; ***p<0.001 One-way ANOVA followed by Dunnett’s test vs. Vehicle MT-200 = a5β1/av small molecule inhibitor; (100 mg/kg, PO BID). SOC = Macit
Slide 33: α5β1 Inhibition Blocks Smooth Muscle Cell Proliferation in Human PAH Lung Slices
Study assessed the use of precision cut lung slices (PCLS) from human PAH patients to assess vascular remodeling ex vivo Impressive inhibition of pulmonary artery remodeling achieved in this human system 33 a5β1 Inhibition Blocks Pulmonary Artery Smooth Muscle Cell Proliferation in Human PAH Lung Sl
Slide 34: αvβ8 Small Molecule Integrin Inhibitor Program
avβ8 Small Molecule Integrin Inhibitor Program for Myelofibrosis and Immuno-oncology 34 Small molecule inhibitors of the αvβ8 integrin in preclinical development avβ8 Program αvβ8 inhibition suppresses activation of TGFβ isoforms 1 and 3 Indications Myelofibrosis; Combination therapy for solid tumor
Slide 35: MORF-088: αvβ8 Inhibitor for Myelofibrosis
MORF-088: αvβ8 Inhibitor for Myelofibrosis (MF) • MF: multi-mechanistic etiology including TGF-B • Blockbuster rare disease indication – Jakafi $1 billion MF sales alone • No disease modifying Tx except allogeneic hematopoietic stem cell transplant • Current SoC has multiple deficiencies • Toxicity:
Slide 36: αvβ8 Inhibition: Central Role in TGF-β Modulation
36 avβ8 Inhibition: Central Role in TGF-b Modulation HD MF HEL 0.000 0.001 0.002 0.003 0.004 0.005 ITGB8 G e n e E x p . re la ti v e t o G A P D H 0.0402 HD MF JVM-2 0.000 0.001 0.002 0.003 0.004 0.005 ITGB6 G e n e E x p . re la ti v e t o G A P D H 0.5566 Healthy donor (HD) and myelofibrosis (MF)
Slide 37: Deep Specialist Expertise Across Management and Board of Directors
Deep Specialist Expertise Across Management, and Board of Directors Gustav Christensen, MBA Chairman Morphic Board, former CEO, Dyax Timothy Springer, PhD Founder, Morphic Therapeutic, Member of Morphic Scientific Advisory Board; Latham Family Professor, Professor of Biological Chemistry and Molecul
Slide 38: Thank You
THANK YOU